Find out everything you need to know about taking ACTEMRA.
See how adults with GCA responded to ACTEMRA in clinical trials.
You may qualify for help paying for ACTEMRA, even if you are underinsured or on Medicare.
ACTEMRA® (tocilizumab) is a prescription medicine that is designed to block the interleukin-6 (IL-6) receptor to dampen inflammatory signaling in blood vessels. In patients with giant cell arteritis (GCA), overactive IL-6 signaling contributes to vessel inflammation and damage
ACTEMRA is administered as either an infusion or a subcutaneous injection. The recommended dosing for GCA is 6 mg/kg IV every 4 weeks in combination with a tapering glucocorticoid regimen, or 162 mg SC once weekly (or, in some cases, every other week based on clinical considerations) alongside a glucocorticoid taper. Talk to your healthcare provider to learn about transitioning between administration routes.
Typical side effects include sinus infections, headache, higher blood pressure, and injection-site reactions. Serious risks are similar to RA: serious infections, gastrointestinal perforation, hepatotoxicity, neutropenia, thrombocytopenia, and hypersensitivity. Baseline and ongoing monitoring (CBC, liver enzymes, lipids) is required. See your doctor right away if you develop fever, severe abdominal pain, jaundice, or signs of allergic reaction. Do not take ACTEMRA if you are allergic to tocilizumab, or any of the ingredients in ACTEMRA.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.